Metabolic dysregulation in Alzheimer's disease: Mechanisms, markers, and therapeutic prospects.

Emerging therapeutic targets beyond amyloid and tau in Alzheimer's Disease: Implications for lifestyle, metabolism and preventive medicine.

Current evidence on emerging treatment strategies beyond the classical amyloid and tau paradigm is summarized, with particular emphasis on microglial activation, mitochondrial function, autophagy, and lipid homeostasis.

From systems to cells: metabolic mechanisms underlying risk divergence in Alzheimer's disease and amyotrophic lateral sclerosis.

Epidemiological studies show an inverse relationship between metabolic disorders and two major neurodegenerative diseases, Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Obesity, type 2 diabetes (T2DM), and reduced physical activity increase AD risk, whereas in ALS cardiometabolic factors, particular...

Translating Molecular Pathogenesis into Therapeutics: Emerging Strategies and Clinical Prospects for Alzheimer’s Disease

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide and poses a major global health challenge. This complex disease involves multiple pathogenic factors, including amyloid-beta (Aβ), tau protein aggregation, synaptic dysfunction, mitochondrial impairment, oxida...

Reframing Alzheimer’s Disease Through a Redox-Metabolic Framework

Alzheimer’s disease (AD) has been conceptualised as a proteinopathy driven by amyloid-β plaques and hyperphosphorylated tau neurofibrillary tangles. AD should not be understood as exclusively a proteinopathy or a metabolic/redox disorder, but as a network of interacting processes in which metabolic dysfunction, mitocho...

Blood biomarkers of oxidative stress and mitochondrial dysfunction in Parkinson's disease and Alzheimer's disease.

The role of microglia glucose metabolism reprogramming in Alzheimer's disease treatment

This review systematically outlines the fundamental characteristics of microglial glucose metabolism and focuses on how the dynamic metabolic reprogramming it undergoes during AD progression regulates microglial immune behavior and inflammatory responses.